Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 versus INOCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 versus INOCOR.
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% vs INOCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine is a direct-acting inotropic agent primarily stimulating β1-adrenergic receptors, with mild β2 and α1 activity, increasing cardiac contractility and stroke volume.
Inocor (amrinone) is a phosphodiesterase III inhibitor that increases intracellular cAMP in cardiac and vascular smooth muscle, leading to positive inotropic effects and vasodilation.
IV continuous infusion: 2.5-20 mcg/kg/min titrated to hemodynamic response; start at 2.5-5 mcg/kg/min. Max dose: 40 mcg/kg/min.
Initial intravenous bolus of 0.75 mg/kg over 2-3 minutes, followed by a continuous infusion of 5-10 mcg/kg/min. Maximum dose: 10 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2 minutes. Short half-life necessitates continuous intravenous infusion for sustained hemodynamic effect.
Terminal elimination half-life: 2.4 hours in normal renal function; prolonged in renal impairment (up to 6 hours in ESRD).
Primarily renal (urinary) elimination; majority as metabolites (3-O-methyldobutamine and conjugates). Less than 5% excreted unchanged in urine. Minor biliary/fecal excretion.
Primarily renal (80%) as unchanged drug; 20% biliary/fecal.
Category C
Category C
Inotropic Agent
Inotropic Agent